Spectral Medical Q1 FY26 loss narrows to CAD 2.94 million; revenue rises 56% to CAD 891,000

  • Spectral Medical posted revenue of CAD 891,000, up 56% year over year.
  • Net loss narrowed to CAD 2.94 million, or CAD 0.01 per share.
  • Operating expenses fell 72% to CAD 3.63 million, driven by lower fair value adjustments on derivative liabilities.
  • Targeting FDA PMA submission for Toraymyxin on May 29, 2026, with topline 12-month mortality data from Tigris expected in June 2026.
  • Vantive agreed to advance USD 1 million as partial funding of Tranche D ahead of PMA filing acceptance, with remaining USD 1 million still tied to the original milestone conditions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spectral Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605080730PRIMZONECNPR____9716302) on May 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.